Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer

7Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: We aimed to demonstrate the effects of tumor treating fields (TTFields) in head and neck squamous cell carcinoma (HNSCC) cells when combined with radiotherapy (RT) and chemotherapy. Methods: Two human HNSCC cell lines (Cal27, FaDu) received five different treatments: TTFields, RT +/− TTFields and RT + simultaneous cisplatin +/− TTFields. Effects were quantified using clonogenic assays and flow cytometric analyses of DAPI, caspase-3 activation and γH2AX foci. Results: Treatment with RT + TTFields decreased the clonogenic survival as strong as treatment with RT + simultaneous cisplatin. The triple combination of RT + simultaneous cisplatin + TTFields even further decreased the clonogenic survival. Accordingly, combination of TTFields with RT or RT + simultaneous cisplatin increased cellular apoptosis and DNA double-strand breaks. Conclusion: TTFields therapy seems a promising combination partner in the multimodal treatment of locally advanced HNSCC. It could be used to intensify chemoradiotherapy or as alternative to chemotherapy.

Cite

CITATION STYLE

APA

Regnery, S., Franke, H., Held, T., Trinh, T., Naveh, A., Abraham, Y., … Adeberg, S. (2023). Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer. Head and Neck, 45(4), 838–848. https://doi.org/10.1002/hed.27298

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free